Paper Details

  1. Home
  2. Paper Details

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Author: BarrPaul M, BarrientosJacqueline, BraggioEsteban, CashenAmanda F, CoutreSteven E, ErbaHarry, HansonCurtis A, JelinekDiane F, KayNeil E, LeisJose F, LittleRichard F, LitzowMark, MatoAnthony R, MullaneMichael P, O'BrienSusan, ShanafeltTait D, SinghAvina K, StoneRichard M, TallmanMartin, WangXin V, ZhangCong C

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

Ibrutinib-rituximab was superior to a standard chemoimmunotherapy regimen in patients with previously untreated chronic lymphocytic leukemia (CLL).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have been limited. METHODS: In a phase 3 trial, we ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31365801

データ提供：米国国立医学図書館（NLM）

Treating Chronic Lymphocytic Leukemia: A New Oasis in the Desert of Cancer

I'm Dr. Camel, and I'm always on the lookout for new strategies in the battle against cancer. This study compares two treatment regimens for chronic lymphocytic leukemia (CLL), a type of blood cancer. It's like exploring two different paths through a desert landscape, seeking the most effective route to recovery.

Ibrutinib-Rituximab: A Promising New Route

The study found that ibrutinib-rituximab was superior to standard chemoimmunotherapy in terms of progression-free survival and overall survival. It's like discovering a hidden oasis that offers a more fertile and life-sustaining environment. The results are promising, suggesting that ibrutinib-rituximab may be a valuable new option for patients with CLL.

Hope and Resilience in the Face of Cancer

This study offers a glimmer of hope for patients with CLL. It highlights the importance of ongoing research and the development of new treatments that can improve outcomes for those facing this challenging disease. It's like finding a new source of water in a parched desert, offering a chance for survival and a healthier future.

Dr.Camel's Conclusion

This phase 3 trial provides compelling evidence for the efficacy of ibrutinib-rituximab in treating chronic lymphocytic leukemia. It's like finding a new path through the desert, leading to a more promising future for patients. This research underscores the importance of ongoing innovation in cancer treatment and the need for personalized approaches to care.
Date :
  1. Date Completed 2019-08-07
  2. Date Revised 2023-05-05
Further Info :

Pubmed ID

31365801

DOI: Digital Object Identifier

NIHMS1536858

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.